ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
US11318097B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 23, 2020 |
| Grant date | May 3, 2022 |
| Priority date | — |
| Expiry date | Jan 23, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/907
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are liposomal vesicles comprising at least a first lipid bilayer and a second lipid bilayer, and a plurality of crosslinkages between the first lipid bilayer and the second lipid bilayer, wherein the plurality of crosslinkages comprise boronic ester or thioketal bonds. Also provided are pharmaceutical compositions comprising the liposomal vesicles described herein and a pharmaceutically acceptable excipient. Also provided are methods of making and using the liposomal vesicles. Thus, a method of treating a subject with a disease comprising administering to the subject a pharmaceutical composition comprising the liposomal vesicles is described herein. Methods of making multilamellar liposomal vesicles responsive to reactive oxygen species are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.